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Introduction
The impact of positive surgical margins (PSM) in partial nephrectomy (PN) has been a controversy. Previous studies on the relationship between PSM and overall survival (OS) were either underpowered or had highly dissimilar groups. We used the National Cancer Database with propensity score matching to determine the association between PSM and OS after PN.
Materials and Methods
We identified patients with T1/T2N0M0 renal cancer treated with PN between 2004 and 2009, and divided them into 2 groups based on their margin status. We used propensity score matching to ensure similarities in age, comorbidity score (CCI), tumor size,
Introduction
The impact of positive surgical margins (PSM) in partial nephrectomy (PN) has been a controversy. Various studies showed conflicting results regarding the associations between PSM and progression-free, 1 -7 cancer-specific, 5, 8, 9 as well as overall survivals (OS). 5, 8, 10 A multi-centered study 5 and a study based on the Ontario Cancer Registry 8 found no associations between PSM and OS, but the statistical powers of both studies were limited by small sample sizes. A more recent study based on the National Cancer Database (NCDB) involved a cohort of 6038 patients who underwent PN for clinical T1 or T2 disease, and found PSM to be associated with an increased risk of all-cause mortality. 10 However, the PSM group in this study had significantly older patients with higher comorbidity scores compared to the negative surgical margins (NSM) group, so there might be confounding effects from other covariates. To determine the association between PSM and OS, a study that has a large sample size yet similar groups for comparison would be ideal.
Therefore, we used the latest NCDB participant user file (PUF) to determine if PSM has an impact on OS after PN in the contemporary clinical setting, with statistical matching to ensure similarities in key covariates between groups.
Materials and Methods
The institutional review board approved this study (protocol number: 1611211043, approval date: December 7, 2016). Committee on Cancer Stage Manual, 7 th Edition. 12 The cases were screened to identify those treated with PN, according to the data item 'Surgical Procedure of the Primary Site at any CoC Facility' with the code 30 representing PN, and were classified into two groups based on surgical margin status. Duration of follow-up was defined by the data item ''Last Contact or Death, Months from Dx' as the time between the date of initial diagnosis and the date on which the patient was last contacted or died, and survival status at the end of follow-up was defined by the data item 'PUF Vital Status'. Patients with missing data on surgical margin status or survival status were excluded.
The endpoint of our study was OS in the PSM and NSM groups. Covariates included age, gender, race, Charlson-Deyo comorbidity score (CCI), tumor size, histology and grade. Figure 1 summarizes the process of patient selection prior to statistical matching.
We recoded ratio covariates into clinically meaningful categories for statistical analysis.
We first performed multivariate logistic regression to identify predictors for PSM. This was followed by propensity score matching with fuzz factor set at 0, giving priority to exact matches and without replacement in sampling, to produce a PSM and a NSM With reference to clear cell RCC, papillary and chromophobe tumors were associated with decreased risks of all-cause mortality (HR: 0.719, 0.341; p=0.020, <0.001 respectively). Sarcomatoid tumors had a HR of 1.724 though this was not statistically significant, again likely due to the very low numbers within this category after matching.
Gender, race and tumor grade did not seem to have significantly different HRs for allcause mortality compared to their respective reference categories. Table 3 illustrates the Cox multiple regression model estimating the HRs for all-cause mortality among the various categories of covariates in our study. Table 4 illustrates the HRs for all-cause mortality due to PSM among patients in specific subgroups of age, CCI, tumor size, histology and grade, with reference to those with NSM in the same subgroups.
Discussion
The basis of PN is nephron preservation, which is associated with improved postoperative renal function, reduced renal and cardiovascular complications and better OS. 13, 14 On the oncologic aspect, PN has an incidence of PSM ranging from 0 to 7%, 15 which is much higher than that of radical nephrectomy. 16 Nonetheless, PN has surpassed RN as the standard surgical option for most localized renal tumors. 17, 18 The clinical impact of PSM in PN has been a controversy. Various multi-centered studies have made conflicting conclusions on whether PSM results in an increased risk of tumor recurrence. 1 -3, 5, 6 Interestingly, most studies found no impact on cancerspecific survival by PSM. 5, 8, 9 It is possible that PSM is associated with increased tumor recurrence without compromising cancer-specific survival due to the slow growth rate of 11 any microscopic residual tumor cells, since the mean annual growth rate of radiologically evident small renal masses is about 0.28cm. 19 It takes a long time for any recurrences to be clinically detectable, and an even longer time to cause cancer-related mortality.
A long duration between PN and any subsequent deaths implies that such mortality is prone to various clinical and non-clinical factors beyond cancer related ones. As such, without discounting the clinical importance of other survivals, OS should also be regarded as one of the more relevant quality control measures after PN. Our study does not include progression-free and cancer-specific survivals as endpoints, due to limitations of the NCDB, but our finding of PSM being associated with a higher risk of all-cause mortality emphasizes the clinical need to reduce PSM at all cost during PN, amidst the various reports that PSM does not affect tumor recurrence and cancerspecific survival. 1, 4, 5, 6, 8, 9 Prior to our findings, only one other study found PSM to have significant impact on OS after PN. 10 caseloads, and no further analysis was done to reduce confounding. 21 Kwon EO et al found imperative indication for PN to be the only significant factor associated with an increased risk of PSM in their multivariate analysis, 7 though this may not be clinically relevant since PN indications are no longer classified into 'absolute', 'relative' and 'elective'. Ani I et al found perinephric fat invasion to be a significant factor for PSM, but pathologic T3-stage tumors did not have statistically significant increased HR in the same multivariate logistic regression model. 8 Our finding that papillary and chromophobe tumors had increased risks for PSM compared to clear cell RCC appeared counter-intuitive. Without further details on the use of pre-operative biopsy and the proportion of cases treated by enucleation, it was difficult to pinpoint why certain histologic subtypes had increased PSM risks.
Based on the findings of these studies, we decided that statistical matching should be performed for age, CCI, tumor size, histology and grade. Since the NCDB does not grades. This highlights the importance to avoid PSM even if pre-operative imaging describes a localized small renal mass or pre-operative biopsy suggests a low grade tumor. Such importance is also applicable among elderly patients, despite the common belief that many of these patients may die with RCC rather than from RCC when there is residual tumor after PN. Due to low numbers, clinical T2a and T2b tumors were combined as a single category in subgroup analysis, though the HR for all-cause mortality due to PSM in this newly formed category still did not achieve statistical significance.
To the best of our knowledge, our study has the largest matched groups to determine the impact of PSM on OS after PN. However, it is not without limitations. Like any other studies based on a retrospective dataset, our findings were vulnerable to any inaccuracies in the NCDB. Statistical matching only accounted for covariates available in the NCDB, and confounding could still occur from various unknown clinical factors.
While propensity score matching helped to reduce selection bias and confounding, a 14 large number of patients with NSM were excluded after matching, significantly reducing the effects of the matched covariates on OS. This is probably the reason that our Cox multiple regression model did not produce statistically significant HRs for gender, race, tumor grade and certain categories of CCI, tumor size and histology, while that by Maurice MJ et al showed some of these covariates as significant factors impacting OS. 10 However, since the primary goal of our study is to determine the effect of PSM on OS, this did not weaken the validity of our conclusion. Longer follow-ups would also be ideal when studying OS after PN, as the number of mortality in the entire matched cohort up to 140 months of follow-up was low (386 deaths in 2530 patients).
Conclusions
Our study found that PSM is associated with worse OS after PN, at 72. 
